The DOI matches its Crossref record.
Cyclophosphamide teratogenesis: A review
Abstract
Cyclophosphamide (CP) is one of the best studied teratogens; it produces primarily central nervous system and skeletal anomalies in rats, mice, rabbits, monkeys, and humans. Furthermore, CP is one of the most extensively studied antienoplastic agents. Recent work using in vitro rodent embryo culture has demonstrated that CP must be bioactivated to be teratogenic. This finding extends earlier work showing that CP must be activated to achieve its antineoplastic and mutagenic effects. Activation of CP to its teratogenic, mutagenic, and antineoplastic form is mediated by microsomal cytochrome P‐450 monooxygenases, which convert CP to 4‐hydroxycyclophosphamide (4OHCP). In the absence of detoxification, 40HCP spontaneously breaks down to phosphoramide mustard (PM) and acrolein (AC). PM is the CP metabolite believed to be responsible for the antineoplastic and mutagenic effects of CP, whereas AC is thought to cause the side effects associated with CP chemotherapy. Recent work has shown that the teratogenic effects of CP are mediated by both PM and AC. Although it is far from proven, available evidence supports the hypothesis that DNA is the primary target in terms of the teratogenic, mutagenic, and antineoplastic effects of CP. Although the nature of the DNA lesions produced by CP, which are responsible for its teratogenic, mutagenic, and antineoplastic effects, is not completely understood, cross‐linking of DNA seems to play a critical role in the antineoplastic properties of CP. Preliminary information obtained from embryos exposed to CP metabolites suggests that, although DNA cross‐linking might play a role in CP teratogenesis, metabolite‐induced DNA strand breakage and/or induction of mutations might also play a role. Although insights into the molecular mechanisms underlying CP teratogenesis are just beginning to accumulate, the availability of in vitro embryo culture combined with the modern armamentarium of molecular biology will allow teratologists to probe further the molecular aspects of teratogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice.
Kohler, S. W., Provost, G. S., Fieck, A., Kretz, P. L., Bullock, W. O., Sorge, J. A., Putman, D. L., & Short, J. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.7958 · Cited by 470
An On-Chip Small Intestine–Liver Model for Pharmacokinetic Studies
Kimura, H., Ikeda, T., Nakayama, H., Sakai, Y., & Fujii, T. (2015) · SLAS Technology · doi:10.1177/2211068214557812 · Cited by 136
“CPA is a prodrug that is bioactivated by cytochrome P450 (CYP) 2B6 monooxygenases to provide the anticancer chemical 4-hydroxycyclophosphamide (4OHCP).(28) In clinical therapy, it is typically given orally, and its bioavailability, which is one of the principal pharmacokinetic properties of drugs, has been reported to…”
Background
Metadata
- Authors
- Mirkes, P. E.
- Venue
- Teratogenesis, Carcinogenesis, and Mutagenesis
- Publisher
- Wiley
- Published
- 1985-01
- Volume
- 5
- Issue
- 2
- Pages
- 75-88
- ISSN
- 0270-3211 (ISSN-L)
- 1520-6866
- OpenAlex
- W1994479261
- Cited by
- 193
- References
- 0
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclophosphamide teratogenesis: A review. https://app.cochat.ai/papers/10.1002/tcm.1770050202
- The paper
- Mirkes, P. E. (1985). Cyclophosphamide teratogenesis: A review. Teratogenesis, Carcinogenesis, and Mutagenesis. https://doi.org/10.1002/tcm.1770050202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.